Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.65 |
| ▸ | CNR1 | P21554 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252422 | 0.83 | SMN1; SMN2 (0.77) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL14367365 | 0.82 | KMT2A (0.70) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL29717171 | 0.80 | CNR2 (0.73) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL5624009 | 0.79 | CNR2 (1.00) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL5623000 | 0.77 | CNR2 (1.00) | CNR2CNR1NPC1RAB9ALMNA | |
| SCHEMBL5626636 | 0.76 | CNR2 (1.00) | CNR2CNR1NPC1RAB9ALMNA | |
| SCHEMBL5624844 | 0.76 | NPC1 (1.00) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL5625255 | 0.76 | CNR2 (0.81) | CNR2CNR1KMT2ANPC1RAB9A | |
| SCHEMBL22433209 | 0.76 | ALDH1A1 (0.69) | CNR2CNR1KMT2ARAB9ALMNA | |
| SCHEMBL5623445 | 0.75 | CNR2 (1.00) | CNR2CNR1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| WO-2006044645-A2 | SULFAMOYL BENZAMIDES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | claimed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885KMT2A 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.